Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Seiji AraiSen Chen

Abstract

Purpose: Clinically available BH3 mimetic drugs targeting BCLXL and/or BCL2 (navitoclax and venetoclax, respectively) are effective in some hematologic malignancies, but have limited efficacy in solid tumors. This study aimed to identify combination therapies that exploit clinical BH3 mimetics for prostate cancer.Experimental Design: Prostate cancer cells or xenografts were treated with BH3 mimetics as single agents or in combination with other agents, and effects on MCL1 and apoptosis were assessed. MCL1 was also targeted directly using RNAi, CRISPR, or an MCL1-specific BH3 mimetic, S63845.Results: We initially found that MCL1 depletion or inhibition markedly sensitized prostate cancer cells to apoptosis mediated by navitoclax, but not venetoclax, in vitro and in vivo, indicating that they are primed to undergo apoptosis and protected by MCL1 and BCLXL. Small-molecule EGFR kinase inhibitors (erlotinib, lapatinib) also dramatically sensitized to navitoclax-mediated apoptosis, and this was associated with markedly increased proteasome-dependent degradation of MCL1. This increased MCL1 degradation appeared to be through a novel mechanism, as it was not dependent upon GSK3β-mediated phosphorylation and subsequent ubiquitylation by...Continue Reading

References

May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Oct 11, 2005·FEBS Letters·Matthew R WarrGordon C Shore
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Jul 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·John R MillsJerry Pelletier
May 13, 2009·Molecular and Cellular Biology·Caroline MorelRoger J Davis
Dec 22, 2009·Nature·Martin SchwickartVishva M Dixit
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Mar 13, 2013·EMBO Reports·Franziska ErtelGordon C Shore
May 13, 2014·Cells·Barbara MojsaSolange Desagher
May 20, 2014·Cancer Discovery·Y Rebecca ChinAlex Toker
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Dec 9, 2014·Experimental Cell Research·Michele ModugnoArturo Galvani
Mar 5, 2015·Proceedings of the National Academy of Sciences of the United States of America·Anthony C FaberJeffrey A Engelman
Mar 10, 2015·Oncotarget·Frédéric R SanterZoran Culig
Apr 24, 2015·Science Translational Medicine·Oliver JonasRobert Langer
Oct 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rui WangYongkui Jing
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Oct 19, 2016·Nature Chemical Biology·Gizem AkçayQibin Su
Oct 28, 2016·Nature·András KotschyOlivier Geneste
Nov 29, 2016·The Journal of Clinical Investigation·Mohamed ElgendySaverio Minucci
Dec 16, 2016·Science Translational Medicine·Gray R AndersonKris C Wood
Jan 1, 2017·Molecular Cancer Research : MCR·Michelle M WilliamsRebecca S Cook

❮ Previous
Next ❯

Citations

Oct 21, 2018·Genes and Immunity·Giuseppe RaschellàAlessandra Gambacurta
May 8, 2020·Clinical and Experimental Pharmacology & Physiology·Jiabei HeWenming Xu
Apr 12, 2020·Journal of Experimental & Clinical Cancer Research : CR·Xinyou YuMing Li
Feb 6, 2019·Proceedings of the National Academy of Sciences of the United States of America·Xiaowei WuZhihua Liu
Feb 19, 2021·Biochimica Et Biophysica Acta. Molecular Cell Research·Sarah Kehr, Meike Vogler
Mar 7, 2021·Cancers·Amaal Ali, George Kulik
Jul 1, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nir Shahar, Sarit Larisch
May 24, 2019·Journal of Medicinal Chemistry·James W PapatzimasDarren J Derksen
Sep 29, 2021·Biochemical Society Transactions·W Douglas Fairlie, Erinna F Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.